iStockAnalyst (press release) | Biogen Idec Inc (BIIB): Pipeline Offers Several Transformational Opportunities iStockAnalyst (press release) Upside potential beyond current estimates would include commercial success of Plegridy and daclizumab in Relapsing Remitting MS (RRMS) and success of Tysabri in secondary progressive multiple sclerosis (SPMS). The company is also betting on the ... |
